Sugi Predict

Sugi Predict / Compounds / SCHEMBL2897207

SCHEMBL2897207

SCHEMBL2897207

CC(c1nnn(-c2cccc(Cl)c2)n1)C(N)c1nnc(-c2cc(F)cc(F)c2)n1C

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 8/20 0.48
▸ PKM P14618 1/20 0.33
▸ MCOLN2 Q8IZK6 4/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2892870 0.81 GRM5 (0.48) GRM5PKMALDH1A1
SCHEMBL5482144 0.81 GRM5 (0.71) GRM5PKMMCOLN2
SCHEMBL2889851 0.81 GRM5 (0.71) GRM5PKMMCOLN2
SCHEMBL2897213 0.80 GRM5 (0.47) GRM5PKMMCOLN2ALDH1A1
SCHEMBL2897209 0.79 GRM5 (0.46) GRM5PKMMCOLN2MEN1NPC1
SCHEMBL2895532 0.73 GRM5 (0.41) GRM5MCOLN2ALDH1A1
SCHEMBL14363428 0.72 GRM5 (0.48) GRM5PKMMEN1NPC1ALDH1A1
SCHEMBL4051271 0.72 GRM5 (0.48) GRM5PKMMEN1NPC1ALDH1A1
SCHEMBL5491722 0.69 GRM5 (0.45) GRM5PKMMEN1NPC1ALDH1A1
SCHEMBL2893177 0.69 GRM5 (0.47) GRM5PKMMEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716125-B1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2013-06-19 — — EP disclosed
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 — — US disclosed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 — — US disclosed
EP-1716125-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS AstraZeneca AB (SE) 2006-11-02 — — EP disclosed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 — — US disclosed
WO-2005080356-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2005-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 GRM5 10/4885PKM 1183/4885MCOLN2 1068/4885
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 GRM5 10/4885PKM 1245/4885MCOLN2 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.